Asset Details
Do you wish to reserve the book?
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Do you wish to request the book?
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
2017
Overview
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of several commonly used chemotherapy drugs including taxanes, vinca alkaloids, and platinum compounds. Development of CIPN is highly variable, both in self-reported symptoms and functional consequences, and can be severe enough to alter dose intensity.
Purpose
To describe the natural histories of both patient-reported symptoms of CIPN and functional impairments in breast cancer patients undergoing taxane-based chemotherapy.
Methods
Thirty-three breast cancer patients (32 female/1 male; 47.8 ± 11.2 years;
n
= 17 stage II/
n
= 16 stage III) were enrolled. Patients completed self-reports of symptoms and function (e.g., EORTC QLQ-CIPN20) and objective measures of physical function (i.e., balance and gait testing) in an outpatient oncology clinic at five timepoints: (1) baseline—prior to starting chemotherapy, (2–4) before starting subsequent chemotherapy cycles, and (5) 1–3 months after receiving their last taxane infusion.
Results
Significant negative changes in both patient-reported outcomes and objective functional measures were observed. Decreased balance was observed after the first chemotherapy cycle (28% increase in medial–lateral excursion of the center of pressure,
p
= 0.016) and progressed with cumulative exposure (43% increase,
p
< 0.001). Patients also demonstrated slower walking speeds (5% decrease,
p
= 0.003) as they progressed through treatment. These functional deficits were mirrored with increased patient-reported symptom severity for all EORTC QLQ-CIPN20 subscales (all
p
< 0.05).
Conclusion
This study longitudinally assessed patient-reported outcomes concurrently with balance and gait testing in patients undergoing taxane therapy. Taxane treatment was associated with the development of clinically relevant problems in both CIPN symptoms and patient function.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
/ Aged
/ Balance
/ Breast Neoplasms - complications
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - physiopathology
/ Bridged-Ring Compounds - administration & dosage
/ Bridged-Ring Compounds - adverse effects
/ Female
/ Gait
/ Humans
/ Male
/ Medicine
/ Oncology
/ Patient Reported Outcome Measures
/ Patients
/ Peripheral Nervous System Diseases - chemically induced
/ Peripheral Nervous System Diseases - physiopathology
/ Platinum
/ Postural Balance - drug effects
/ Pressure
/ Taxanes
/ Taxoids - administration & dosage
/ Toxicity
/ Walking
